The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis
This study examines how changes in gut bacteria, specifically a bacterium called Ruminococcus gnavus, may contribute to the development of spondyloarthritis, a type of inflammatory arthritis. Researchers will collect samples from your intestines and stool and compare them between people with spondyloarthritis and healthy individuals without chronic diseases.
Key Objective: This research may help identify whether specific gut bacteria changes play a role in causing spondyloarthritis, potentially leading to new prevention or treatment strategies.
Who to Consider: People with spondyloarthritis or healthy individuals without chronic diseases who are interested in contributing to research that could improve understanding of this arthritis condition should consider enrolling.
Trial Parameters
Brief Summary
The primary objective of this case-control study aims to explore the role of bacterium Ruminococcus gnavus (R. gnavus) with intestinal biopsy and faecal sampling in the initiation and the development of spondyloarthritis (SPA) in comparison with health control subjets (patients without chronic disease but have indication to digestive endoscopy).
Eligibility Criteria
Inclusion Criteria: Patients with SPA: * Patients ⩾ 18 years; * Diagnosed as spondyloarthritis (SpA) according ASAS classification; * Affiliated to a social security scheme; * Have signed the written informed consent form. Control subjects: * Subjects ⩾ 18 years; * Subjects free of SPA and planned for a digestive endoscopy for another indication such as to explore the risk of colorectal cancer in family member; * Affiliated to a social security scheme; * Have signed the written informed consent form. Exclusion Criteria: * Subjects unable to understand the proposed study and/or sign a informed consent form; * Pregnant women or breast feeding women; * Subjects under guardianship or curatorship; * Have taken antibiotic 1 month prior to inclusion; * Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome; * Refusal of subjects to participate to the study; * Foreign patients under french AME scheme.